NDAORALTABLETPriority Review
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Mechanism of Action
elucidated. Amifampridine is a broad-spectrum potassium channel blocker.
Indications (2)
Clinical Trials (5)
Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
Started Mar 2019
Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients
Started Jan 2019
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Started Jun 2018
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Started Apr 2018
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Started Nov 2016
Loss of Exclusivity
LOE Date
Feb 25, 2037
133 months away
Patent Expiry
Feb 25, 2037